ALGS
Aligos Therapeutics, Inc. NASDAQ Listed Oct 16, 2020$7.46
+33.42%
vs $5.59
Mkt Cap $46.2M
52w Low $3.98
35.8% of range
52w High $13.69
50d MA $5.34
200d MA $7.26
P/E (TTM)
—
EV/EBITDA
—
P/B
1.4x
Debt/Equity
0.1x
ROE
-45.2%
P/FCF
-0.7x
RSI (14)
54.80
ATR (14)
$0.52
Beta
2.62
50d MA
$5.34
200d MA
$7.26
Avg Volume
249.2K
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
One Corporate Drive · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | AMC | -1.09 | -0.14 | +87.2% | 5.51 | -0.2% | +1.5% | — | — | — | — | — |
| May 7, 2026 | AMC | -2.29 | -2.21 | +3.5% | 6.03 | +1.3% | +6.8% | -3.6% | +4.2% | +3.1% | +0.3% | — |
| Mar 5, 2026 | AMC | -2.49 | -1.91 | +23.2% | 6.66 | -3.9% | +4.8% | +0.7% | +1.0% | +6.6% | -2.1% | — |
| Nov 6, 2025 | AMC | -2.09 | -3.04 | -45.5% | 7.10 | -12.4% | -0.4% | -2.5% | -3.0% | -3.3% | -6.0% | — |
| Aug 6, 2025 | AMC | -2.35 | -1.53 | +34.9% | 8.04 | -3.9% | +1.1% | -5.4% | -1.6% | -1.7% | +2.8% | — |
| May 6, 2025 | AMC | -2.80 | -2.11 | +24.6% | 4.58 | +1.1% | -4.8% | +11.7% | -8.0% | +26.8% | +4.6% | — |
| Mar 10, 2025 | AMC | -2.63 | -3.41 | -29.7% | 10.41 | -1.1% | +1.0% | +2.9% | -4.9% | +11.3% | +2.0% | — |
| Nov 6, 2024 | AMC | -2.15 | -3.07 | -42.8% | 9.35 | -2.9% | +6.1% | +2.7% | +37.3% | +27.6% | +9.7% | — |
| Aug 6, 2024 | AMC | -4.00 | 0.75 | +118.8% | 11.18 | +3.9% | +21.9% | +0.0% | +0.9% | -1.5% | -0.5% | — |
| May 7, 2024 | AMC | -4.75 | -5.50 | -15.8% | 19.75 | -0.6% | -0.9% | -0.9% | -5.9% | -6.3% | +1.1% | — |
| Mar 12, 2024 | AMC | -6.75 | -5.50 | +18.5% | 21.75 | +0.0% | +0.0% | -0.0% | +6.0% | -0.2% | +1.3% | — |
| Nov 2, 2023 | AMC | -12.00 | -10.25 | +14.6% | 18.75 | +0.0% | +1.4% | -0.1% | -3.2% | +0.4% | +4.2% | — |
| Aug 3, 2023 | AMC | -12.50 | -10.75 | +14.0% | 22.25 | +5.6% | -0.5% | +1.1% | +5.0% | +3.6% | -0.4% | — |
| May 4, 2023 | AMC | -12.25 | -13.25 | -8.2% | 34.00 | -5.1% | -8.8% | -0.8% | +0.0% | -2.4% | -6.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 28 | Lake Street | Initiates | Buy | $45 | $5.60 | $5.75 | +2.7% | +3.4% | -1.6% | -6.1% | -1.9% | -2.1% |
| May 21 | Cantor Fitzgerald | Initiates | Overweight | $20 | $5.60 | $5.59 | -0.2% | +2.0% | +0.9% | -0.3% | -2.4% | +3.4% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.10 | $7.29 | +2.7% | +6.6% | -2.1% | +2.2% | +2.0% | -5.4% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.88 | $10.71 | -1.6% | -6.2% | -8.1% | -4.5% | +3.0% | +8.4% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.12 | $8.70 | -4.6% | -9.5% | -13.5% | +6.2% | -14.5% | -8.2% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.41 | $10.30 | -1.1% | +1.0% | +2.9% | -4.9% | +11.3% | +2.0% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.35 | $9.08 | -2.9% | +6.1% | +2.7% | +37.3% | +27.6% | +9.7% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.34 | $7.37 | +0.4% | -1.8% | +25.2% | -7.0% | +5.6% | +5.5% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.18 | $10.60 | +4.1% | -10.2% | -11.4% | +0.6% | +0.9% | -2.4% |
| Jan 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $41.00 | $44.75 | +9.1% | +23.2% | +4.5% | -3.8% | +1.5% | -6.3% |
| Jan 6 | Jefferies | Upgrade | Hold → Buy | — | $24.75 | $29.50 | +19.2% | +32.3% | -0.8% | +21.5% | +3.8% | -12.2% |
| Jan 6 | Piper Sandler | Upgrade | Neutral → Overweight | — | $24.75 | $29.50 | +19.2% | +32.3% | -0.8% | +21.5% | +3.8% | -12.2% |
| Nov 3 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $26.75 | $26.25 | -1.9% | -1.9% | -5.7% | -0.4% | -4.4% | -5.2% |
| May 5 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $31.00 | $28.50 | -8.1% | -11.3% | -5.5% | +5.8% | +5.5% | -6.0% |
| Mar 23 | Piper Sandler | Downgrade | Overweight → Neutral | — | $72.50 | $66.75 | -7.9% | -3.8% | -15.4% | -3.4% | -7.5% | +1.2% |
| Mar 23 | SVB Leerink | Maintains | Outperform → Outperform | — | $72.50 | $66.75 | -7.9% | -3.8% | -15.4% | -3.4% | -7.5% | +1.2% |
| Mar 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $61.25 | $63.25 | +3.3% | +5.7% | -5.4% | -3.7% | +9.3% | +6.6% |
| Mar 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $61.25 | $63.25 | +3.3% | +5.7% | -5.4% | -3.7% | +9.3% | +6.6% |
| Feb 16 | SVB Leerink | Maintains | Outperform → Outperform | — | $66.00 | $66.75 | +1.1% | -4.2% | -5.9% | +1.7% | -1.2% | -7.5% |
| Jan 7 | JP Morgan | Downgrade | Overweight → Neutral | — | $114.75 | $111.27 | -3.0% | -14.8% | -4.6% | +6.4% | -5.3% | -11.4% |
| Jan 7 | SVB Leerink | Maintains | Outperform → Outperform | — | $114.75 | $111.27 | -3.0% | -14.8% | -4.6% | +6.4% | -5.3% | -11.4% |
| Sep 9 | SVB Leerink | Maintains | Outperform → Outperform | — | $382.75 | $387.50 | +1.2% | +1.9% | -2.4% | +2.4% | +0.7% | +3.6% |
| Nov 10 | JP Morgan | Maintains | Overweight → Overweight | — | $449.50 | $456.75 | +1.6% | -10.8% | +7.0% | -0.9% | +15.7% | +6.1% |
| Nov 10 | Jefferies | Maintains | Buy → Buy | — | $449.50 | $456.75 | +1.6% | -10.8% | +7.0% | -0.9% | +15.7% | +6.1% |
| Nov 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $449.50 | $456.75 | +1.6% | -10.8% | +7.0% | -0.9% | +15.7% | +6.1% |
No insider trades available.
8-K
Aligos Therapeutics, Inc. -- 8-K Filing
Aligos maintains control over its licensed product while Amoytop retains ownership of manufacturing improvements, with Aligos receiving a perpetual, royalty-free license for improvements outside the territory.
Apr 21
8-K
Unknown — 8-K Filing
Aligos' Fast Track Designation accelerates pevifoscorvir's FDA pathway for hepatitis B, potentially enabling faster approvals and earlier revenue generation if efficacy data proves compelling in ongoing trials.
Apr 14
8-K
Aligos Therapeutics, Inc. -- 8-K Filing
Aligos Therapeutics reported advancing its Phase 2 B-SUPREME study for pevifoscorvir sodium, a potential treatment for liver and viral diseases, signaling progress toward clinical milestones for investors.
Mar 5
8-K
Aligos Therapeutics, Inc. -- 8-K Filing
This summary lacks substantive information about a material event, providing only standard corporate identification details without disclosing any specific transaction, agreement, or business development affecting Aligos Therapeutics investors.
Feb 4
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Avantis U.S. Small Cap Equity ETF | 1,427 | $10K | Feb 2026 |
| 2 | Avantis U.S. Small Cap Equity Fund | 332 | $2K | Feb 2026 |
| 3 | Guggenheim Active Allocation Fund | 5 | $35 | Feb 2026 |
Valuation
Market Cap
$46.2M
Enterprise Value
-$22.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.04x
P/B
1.38x
P/S
2.34x
P/FCF
-0.67x
EV/EBITDA
—
Shares Out
9.9M
Financials (TTM)
Revenue
$31.5M
Net Income
-$76.0M
EBITDA
-$71.2M
Free Cash Flow
-$82.9M
Op Cash Flow
-$82.5M
EPS Basic
$-2.45
EPS Diluted
$-7.30
EPS Forward
$-6.50
Gross Margin
99.2%
Op Margin
-250.6%
Net Margin
-241.0%
Balance Sheet
Total Assets
$88.5M
Total Liab.
$35.0M
Total Equity
$53.5M
Cash
$77.8M
LT Debt
$0
Book Value/Sh
$5.42
Debt/Equity
0.10x
Current Ratio
3.90
Quick Ratio
3.90
Returns & Growth
ROE
-45.2%
ROA
-27.3%
ROIC
-123.9%
Rev Growth YoY
-44.6%
EPS Growth YoY
+88.3%
Price Returns
2W
+37.0%
1M
-16.9%
3M
-13.2%
6M
-23.6%
12M
-27.3%
Technicals
52W High
$13.69
52W Low
$3.98
50d MA
$5.34
200d MA
$7.26
RSI (14)
54.80
ATR (14)
$0.52
Beta
2.62
Avg Volume
249K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$20.00
High
$20.00
Low
$20.00
Median
$20.00
Data updated apr 24, 2026 5:14pm
· Source: financialmodelingprep.com